Fatal Interstitial Pneumonitis Rapidly Developed after the First Cycle of CHOP with Etoposide Combination Chemotherapy in a Patient with Lymphoma.
10.4046/trd.2013.74.5.235
- Author:
Hyung Chul PARK
1
;
Jae Sook AHN
;
Deok Hwan YANG
;
Sung Hoon JUNG
;
In Jae OH
;
Song CHOI
;
Seung Shin LEE
;
Mi Young KIM
;
Yeo Kyeoung KIM
;
Hyeoung Joon KIM
;
Je Jung LEE
Author Information
1. Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea. drjejung@chonnam.ac.kr
- Publication Type:Case Report
- Keywords:
Lymphoma;
Lung Diseases, Interstitial;
Granulocyte Colony-Stimulating Factor;
Drug Therapy
- MeSH:
Cyclophosphamide;
Doxorubicin;
Drug Therapy, Combination;
Etoposide;
Granulocyte Colony-Stimulating Factor;
Humans;
Incidence;
Lung;
Lung Diseases, Interstitial;
Lung Injury;
Lymphoma;
Lymphoma, T-Cell, Peripheral;
Neutropenia;
Prednisolone;
Vincristine
- From:Tuberculosis and Respiratory Diseases
2013;74(5):235-239
- CountryRepublic of Korea
- Language:English
-
Abstract:
Several chemotherapeutic agents are known to develop pulmonary toxicities in cancer patients, although the frequency of incidence varies. Cyclophosphamide is a commonly encountered agent that is toxic to the lung. Additionally, granulocyte colony-stimulating factor (G-CSF) being used for the recovery from neutropenia can exacerbate lung injury. However, most of the patients reported previously that the drug-induced interstitial pneumonitis were developed after three to four cycles of chemotherapy. Hereby, we report a case of peripheral T cell lymphoma which rapidly developed a fatal interstitial pneumonitis after the first cycle of combined chemotherapy with cyclophosphamide, adriamycin, vincristine, prednisolone, and etoposide and the patient had also treated with G-CSF during neutropenic period.
